#United States #Washington #Vanda Pharmaceuticals #IndyCar #NEREUS™

NEREUS™ Powers Forward as the Sponsor of No. 47 IndyCar Entry

Vanda Pharmaceuticals Inc. has taken a significant leap into the world of high-speed racing with its sponsorship of the No. 47 car in the NTT IndyCar Series. This partnership not only highlights the breakthrough medication, NEREUS™ (tradipitant), but also marks a historical moment—47 years since the last new treatment for motion sickness was introduced in the U.S.

A Revolutionary Treatment for Motion Sickness

NEREUS™ has emerged as a groundbreaking solution for the prevention of motion-induced vomiting, representing a modern advancement in medication. As a selective NK-1 receptor antagonist, it is designed specifically for adults suffering from motion sickness, offering hope to millions who contend with this common ailment during travel. Prior to NEREUS™, patients had no new options for nearly five decades, making this approval a highly celebrated event in the pharmaceutical industry.

Mihael H. Polymeropoulos, M.D., President, CEO, and Chairman of Vanda, expressed excitement over this sponsorship, stating, “Partnering with the No. 47 car perfectly captures this historic moment and our shared commitment to performance under challenging conditions.” The agreement aligns the innovative aspirations of NEREUS™ with the fast-paced and demanding environment of IndyCar racing, where focus and stability are paramount.

A Suitable Match in the Racing World

The No. 47 is driven by an accomplished team, Rahal Letterman Lanigan Racing, which boasts a history of championship victories. Featuring NEREUS™ branding prominently across select events in the 2026 NTT IndyCar Series, the team aims to merge the worlds of pharmaceuticals and sports, creating a platform for awareness and education surrounding motion sickness.

Visibility and Engagement at High Speeds

Throughout the 2026 racing season, the fans watching the IndyCar Series will see the NEREUS™ branding in action, capturing the attention of a wide audience. This visibility is not just about marketing; it’s also an opportunity to engage potential patients in conversations about motion sickness treatment options that weren't previously available.

Conclusion: A Milestone for Patients and Brands

As Vanda Pharmaceuticals moves forward with its initiatives, the NEREUS™ sponsorship presents a unique opportunity to celebrate both a milestone in pharmaceutical innovation and the thrilling world of motorsports. With motion sickness being a prevalent issue faced by many travelers, the hope is that this partnership will inspire greater awareness and ultimately better health outcomes for those affected.

For those interested in learning more about Vanda Pharmaceuticals and their commitment to innovative therapies, you can visit their official website at vandapharma.com, where they continue to update on advancements and initiatives like NEREUS™ and its impact on patient care.